Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharming Group N.V. ADR (PHAR)

Pharming Group N.V. ADR (PHAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pharming Group Announces Restructuring to Cut Costs and Boost Growth

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

PHAR : 17.80 (-1.60%)
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...

OTLK : 1.8200 (-0.55%)
KNSA : 42.00 (-1.15%)
CRMD : 12.53 (+2.79%)
PHAR : 17.80 (-1.60%)
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation.The...

KNSA : 42.00 (-1.15%)
CRMD : 12.53 (+2.79%)
CPRX : 24.35 (-0.41%)
PHAR : 17.80 (-1.60%)
Pharming Group to participate in September investor conferences

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the...

PHAR : 17.80 (-1.60%)
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled...

PHAR : 17.80 (-1.60%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

KA : 0.5746 (-30.69%)
XFOR : 4.50 (+1.81%)
PHAR : 17.80 (-1.60%)
APRE : 0.9802 (+3.05%)
Pharming Group to report second quarter and first half 2023 financial results on August 3

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter...

PHAR : 17.80 (-1.60%)
Pharming announces sale of priority review voucher

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive...

PHAR : 17.80 (-1.60%)
Pharming Group to attend the following Investor Conferences in June

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following...

PHAR : 17.80 (-1.60%)
Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues...

PHAR : 17.80 (-1.60%)

Barchart Exclusives

The Next Market Collapse Will Be Quiet And That Is Exactly Why Investors Will Miss It
The next market collapse will start silently beneath the surface, and only investors who watch structure rather than headlines will see it coming Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar